Institutional Investor 667, L.P. Files Intent to Sell Shares, Part of Larger Baker Brothers Group Liquidation
Summary
667, L.P., an affiliate of Baker Brothers Life Sciences, L.P., filed a Form 144 indicating intent to sell 38,277 shares, contributing to a combined group sale of 500,000 shares.
Key Events
-
Intent to Sell Shares
667, L.P. filed a Form 144 to sell 38,277 shares of Protara Therapeutics common stock, with an approximate market value of $223,920.00.
-
Affiliated Group Sale
This sale is part of a larger, combined intent by the Baker Brothers Life Sciences affiliated group to sell a total of 500,000 shares.
-
Ongoing Liquidation
This filing is the latest in a pattern of Form 144s from the Baker Brothers group, indicating a sustained reduction in their stake following recent positive news.
Analysis
This Form 144 from 667, L.P. signals a continued reduction in holdings by the Baker Brothers affiliated group, which collectively intends to sell 500,000 shares. This follows a series of similar filings from the same institutional investor group over the past two weeks, indicating an ongoing liquidation strategy. The selling activity occurs shortly after the company announced positive interim clinical trial results, suggesting the investor group may be capitalizing on market strength to exit their position. This persistent selling by a major institutional holder could create an overhang on the stock, especially when combined with the concurrent 424B7 filing introducing other new selling stockholders.
At the time of this filing, TARA was trading at $5.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $304.6M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.